Rheumatoid Arthritis [2017]: Bulletin #2
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson announcing the FDA’s rejection of Plivensia (sirukumab); Can-Fite concluding its cardiodynamic trial for piclidenoson (CF 101) and being given approval to begin a global Phase III trial in patients with RA; and AbbVie announcing data from the Phase III SELECT-NEXT trial for upadacitinib in patients with RA.
Business Questions:
Business Questions:
- How do KOLs regard Plivensia and what are its chances of coming to market?
- How would Plivensia fare against other IL-6 inhibitors for RA?
- According to KOLs, what lies ahead for IL-6 inhibitors as a class?
- How do KOLs view the piclidenoson ACRobat study versus methotrexate?
- If approved, how would piclidenoson be prescribed?
- Does upadacitinib differentiate itself from other JAK inhibitors?
More Publications
Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
US$ 995.00
February 2016
-
Medical Affairs Reputations (EU5) [Cancer Pain]
US$ 6,175.00
July 2017
-
NPS+ Psoriasis (EU5)
US$ 2,495.00
April 2016
-
Medical Affairs Reputations: Asthma/COPD (EU)
US$ 4,995.00
October 2016
-
The Rise of Wearable Healthcare Technology: Opportunities and Challenges for Pharma
US$ 595.00
February 2015
-
